, Volume 215, Issue 4, pp 655–663 | Cite as

A preliminary investigation of varenicline for heavy drinking smokers

Original Investigation



Varenicline, an approved smoking cessation pharmacotherapy, also shows promise as a potential treatment for alcohol dependence. However, varenicline has not been tested in heavy drinkers, and it remains to be determined whether varenicline could reduce alcohol craving and consumption in smokers who are trying to quit smoking.


We conducted a preliminary study to examine the effect of varenicline on drinking behavior and the effects of extended varenicline pretreatment on smoking.


Thirty heavy drinking smokers received smoking cessation counseling and were randomly assigned to receive either an extended 4-week pretreatment with varenicline 2 mg daily or the usual 1-week pretreatment. Those in the extended pretreatment group received active medication for 8 weeks (i.e., 4 weeks of active pre-treatment followed by 4 weeks of active treatment), and participants in the usual pretreatment group received active medication after a placebo lead in (i.e., 3 weeks of placebo followed by active medication for 5 weeks).


Participants who received varenicline during the first 3 weeks reported significantly greater reductions in alcohol craving and numerically fewer heavy drinking days compared to those who received placebo, and these differences persisted during the open-label phase. Extended pretreatment was associated with numerically greater reductions in cigarette smoking over the entire study period. There were no differences, however, in smoking abstinence rates following the smoking quit date between the two groups.


Findings from this preliminary study suggest that varenicline may be a promising strategy for concurrently reducing heavy drinking and promoting smoking changes in heavy drinkers.


Smoking cessation Varenicline Heavy drinking Alcohol craving 


  1. Abrams DB, Rohsenow DJ, Niaura RS, Pedraza M, Longabaugh R, Beattie MC, Binkoff JA, Noel NE, Monti PM (1992) Smoking and treatment outcome for alcoholics: effects on coping skills, urge to drink, and drinking rates. Behav Ther 23:283–297CrossRefGoogle Scholar
  2. Anton RF, Moak DH, Latham P (1995) The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19:92–99. doi:10.1111/j.1530-0277.1995.tb01475.x PubMedCrossRefGoogle Scholar
  3. Baltieri DA, Daró FR, Ribeiro PL, De Andrade AG (2009) Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 103:2035–2044. doi:10.1111/j.1360-0443.2008.02355.x CrossRefGoogle Scholar
  4. Coe JW, Brooks PR, Vetelino MG et al (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477PubMedCrossRefGoogle Scholar
  5. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale, NJGoogle Scholar
  6. Cooney JL, Cooney NL, Patten CA, George TP (2004) Comorbidity of nicotine dependence with affective, psychotic and substance use disorders. In: Kranzler HR, Tinsley JA (eds) Dual diagnosis and psychiatric treatment: substance abuse and comorbid disorders, 2nd edn. Marcel Dekker, New York, pp 211–259Google Scholar
  7. Davis TJ, de Fiebre CM (2006) Alcohol’s actions on neuronal nicotinic acetylcholine receptors. Alcohol Res Health 9:179–185Google Scholar
  8. Dawson D (2000) Drinking as a risk factor for sustained smoking. Drug Alcohol Depend 59:235–249PubMedCrossRefGoogle Scholar
  9. Durazzo T, Cardenas V, Studholme C, Weiner M, Meyerhoff D (2007) Non-treatment-seeking heavy drinkers: effects of chronic cigarette smoking on brain structure. Drug Alcohol Depend 87:76–82PubMedCrossRefGoogle Scholar
  10. Ericson M, Löf E, Stomberg R, Söderpalm B (2009) The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther 329:225–230PubMedCrossRefGoogle Scholar
  11. Fiore M, Jaen C, Baker T et al (2008) Treating tobacco use and dependence, 2008 update. Clinical practice guideline. USDHHS, Public Health Service, RockvilleGoogle Scholar
  12. First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured clinical interview for DSM-IV Axis I Disorders, research version, patient edition. Biometrics Research, New York State Psychiatric Institute, New YorkGoogle Scholar
  13. Gonzales D, Rennard SI, Nides M et al (2006) Varenicline, an alpha-4-beta-2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55PubMedCrossRefGoogle Scholar
  14. Grant BF, Hasin DS, Chou SP et al (2004) Nicotine dependence and psychiatric disorders in the United States. Arch Gen Psychiatry 61:1107–1115PubMedCrossRefGoogle Scholar
  15. Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR (2010) Activation of 4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci 30:10169–10176PubMedCrossRefGoogle Scholar
  16. Hintz T, Mann K (2007) Long-term behavior in treated alcoholism: evidence for beneficial carry-over effects of abstinence from smoking on alcohol use and vice versa. Addict Behav 32:3093–3100PubMedCrossRefGoogle Scholar
  17. Hughes JR (1995) Clinical implications of the association between smoking and alcoholism. In: Fertig J, Allen JP (eds) Alcohol and tobacco: from basic science to clinical practice (NIAAA research monograph no. 95-3931). Government Printing Office, WashingtonGoogle Scholar
  18. Johnson BA, Ait-Daoud N, Bowden CL et al (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677–1685PubMedCrossRefGoogle Scholar
  19. Johnson B, Ait-Daoud N, Roache J (2005) The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol 66:157–167Google Scholar
  20. Johnson BA, Rosenthal N, Capece JA et al (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–1651PubMedCrossRefGoogle Scholar
  21. Jorenby DE, Hays JT, Rigotti NA et al (2006) Efficacy of varenicline, an alpha-4-beta-2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63PubMedCrossRefGoogle Scholar
  22. Kahler C, Borland R, Hyland A, McKee S, Thompson M, Cummings K (2009) Alcohol consumption and quitting smoking in the International Tobacco Control (ITC) Four Country Survey. Drug Alcohol Depend 100:214–220PubMedCrossRefGoogle Scholar
  23. Kahler C, Borland R, Hyland A, McKee S, Thompson M, Cummings K (2010) Alcohol consumption and quitting smoking in the International Tobacco Control (ITC) Four Country Survey. Drug Alcohol Depend 110:101–107PubMedCrossRefGoogle Scholar
  24. Kamens HM, Andersen J, Picciotto MR (2010) Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology 208:613–626PubMedCrossRefGoogle Scholar
  25. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335–1341. doi:10.1111/j.1530-0277.2001.tb02356.x PubMedCrossRefGoogle Scholar
  26. Kuper H, Tzonou A, Kaklamani E et al (2000) Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85:498–502PubMedCrossRefGoogle Scholar
  27. Leeman RF, Huffman CJ, O’Malley SS (2007) Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release, and varenicline trials: a review. Alcohol Alcohol 42:196–206PubMedGoogle Scholar
  28. Leeman R, McKee S, Toll B et al (2008) Risk factors for treatment failure in smokers: relationship to alcohol use and to lifetime history of an alcohol use disorder. Nicotine Tob Res 10:1793–1809PubMedCrossRefGoogle Scholar
  29. Levine J, Schooler NR (1986) SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22:343–381PubMedGoogle Scholar
  30. Lowenfels A, Maisonneuve P, Cavallini G et al (1994) Prognosis of chronic pancreatitis: an international multicenter study. International Pancreatitis Study Group. Am J Gastroenterol 89:1467–1471PubMedGoogle Scholar
  31. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM (1993) Development and validation of the biphasic alcohol effects scale. Alcohol Clin Exp Res 17:140–146PubMedCrossRefGoogle Scholar
  32. Mason B, Lehert P (2009) Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy. J Addict Med 3:164–171CrossRefGoogle Scholar
  33. McKee SA, Harrison EL, O'Malley SS et al (2009) Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 66:185–190PubMedCrossRefGoogle Scholar
  34. National Institute on Alcohol Abuse and Alcoholism (2004) NIAAA council approves definition of binge drinking. NIAAA NewsletterGoogle Scholar
  35. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R et al (2006) Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166:1561–1568PubMedCrossRefGoogle Scholar
  36. O’Malley SS (2008) An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence. Arch Gen Psychiatry 65:135–144PubMedCrossRefGoogle Scholar
  37. Obach RS, Reed-Hagen AE, Krueger SS et al (2006) Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121–130PubMedCrossRefGoogle Scholar
  38. Osler M, Prescott E, Godtfredsen N, Hein H, Schnohr P (1999) Gender and determinants of smoking cessation: a longitudinal study. Prev Med 29:57–62PubMedCrossRefGoogle Scholar
  39. Pelucchi C, Gallus S, Garavello W, Bosetti C, La Vecchia C (2006) Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. Alcohol Res Health 29:193–198PubMedGoogle Scholar
  40. Pettinati HM, Rabinowitz AR (2006) Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep 8:383–388PubMedCrossRefGoogle Scholar
  41. Posner K, Oquendo MA, Gould M, Stanley B, Davies M (2007) Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035–1043PubMedCrossRefGoogle Scholar
  42. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007) Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28:316–325PubMedCrossRefGoogle Scholar
  43. Rose JE, Behm FM, Westman EC, Kukovich P (2006) Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 8:89–101PubMedCrossRefGoogle Scholar
  44. Sobell LC, Sobell MB (2003) Alcohol consumption measures. In: Allen JP, Wilson VB (eds) Assessing alcohol problems: a guide for clinicians and researchers, 2nd edn. National Institute on Alcohol Abuse and Alcoholism, Bethesda, pp 75–99Google Scholar
  45. SRNT Subcommittee on Biochemical Verification (Benowitz NL, Jacob P, Ahijevych K, Jarvis MJ, Hall S, LeHouezec J, Hansson A, Lichtenstein E, Henningfield J, Tsoh J, Hurt RD, Velicer, W) (2002) Biochemical verification of tobacco use and cessation. Nicotine Tob Res 4:149–159CrossRefGoogle Scholar
  46. Steensland P, Simms JA, Holgate J, Richards JK, Bardett SE (2007) Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. PNAS 104:12518–12523PubMedCrossRefGoogle Scholar
  47. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-AR). Br J Addict 84:1353–1357PubMedCrossRefGoogle Scholar
  48. Toll BA, Leary V, Wu R, Salovey P, Meandzija B, O’Malley SS (2008) A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addict Behav 33:173–179PubMedCrossRefGoogle Scholar
  49. Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O’Malley SS (2010) Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug Alcohol Depend 111:200–206PubMedCrossRefGoogle Scholar
  50. Vaillant G, Schnurr P, Baron J, Gerber P (1991) A prospective study of the effects of cigarette smoking and alcohol abuse on mortality. J Gen Intern Med 6:299–304PubMedCrossRefGoogle Scholar
  51. Zimmerman R, Warheit G, Ulbrich P, Auth J (1990) The relationship between alcohol use and attempts and success at smoking cessation. Addict Behav 15:197–207PubMedCrossRefGoogle Scholar
  52. Znaor A, Brennan P, Gajalakshmi V, Mathew A, Shanta V, Varghese C et al (2003) Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men. Int J Cancer 105:681–686PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Lisa M. Fucito
    • 1
  • Benjamin A. Toll
    • 1
    • 2
    • 3
  • Ran Wu
    • 1
  • Denise M. Romano
    • 1
  • Ece Tek
    • 1
  • Stephanie S. O’Malley
    • 1
    • 2
  1. 1.Department of Psychiatry, CMHC-S200Yale University School of MedicineNew HavenUSA
  2. 2.Yale Cancer CenterNew HavenUSA
  3. 3.Smilow Cancer Hospital at Yale–New HavenNew HavenUSA

Personalised recommendations